Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sanofi, GSK offer 20M COVID-19 vaccine doses to COVAX alliance

By Brian Buntz | October 29, 2020

GSK SanofiSanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, have signaled their intent to work with the legal administrator of the COVAX Facility.

The two companies have vowed to produce 200 million doses of a vaccine based on the protein subunit AS03 adjuvant. 

Governments, businesses and health organizations have banded together to support the COVAX Facility, which aims to ensure global equitable access to vaccines to treat the novel coronavirus.  

The initiative could potentially address the development of vaccine nationalism, the nationalistic tendency to prioritize vaccines that could cost the world $1.2 trillion, according to estimates from the Rand Europe. 

The two companies announced their plan to supply up to 60 million doses to the U.K.

The vaccine candidate from the Franco-British partnership, however, trails rivals with Phase 3 COVID-19 vaccine trials including Moderna (NSDQ:MRNA), Janssen (NYSE:JNJ), Pfizer (NYSE:PFE) and AstraZeneca (LON:AZN). 

Sanofi and GSK launched a Phase 1/2 trial on September 3 with 440 subjects enrolled. The companies anticipate first results from that trial in early December 2020. Sanofi and GSK hope to launch a Phase 3 trial before the end of 2020. 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, GSK, Sanofi
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50